Comparing predictions among competing risks models with time‐dependent covariates

Prediction of cumulative incidences is often a primary goal in clinical studies with several endpoints. We compare predictions among competing risks models with time‐dependent covariates. For a series of landmark time points, we study the predictive accuracy of a multi‐state regression model, where the time‐dependent covariate represents an intermediate state, and two alternative landmark approaches. At each landmark time point, the prediction performance is measured as the t‐year expected Brier score where pseudovalues are constructed in order to deal with right‐censored event times. We apply the methods to data from a bone marrow transplant study where graft versus host disease is considered a time‐dependent covariate for predicting relapse and death in remission. Copyright © 2013 John Wiley & Sons, Ltd.     

Meta‐STEPP: subpopulation treatment effect pattern plot for individual patient data meta‐analysis

We have developed a method, called Meta‐STEPP (subpopulation treatment effect pattern plot for meta‐analysis), to explore treatment effect heterogeneity across covariate values in the meta‐analysis setting for time‐to‐event data when the covariate of interest is continuous. Meta‐STEPP forms overlapping subpopulations from individual patient data containing similar numbers of events with increasing covariate values, estimates subpopulation treatment effects using standard fixed‐effects meta‐analysis methodology, displays the estimated subpopulation treatment effect as a function of the covariate values, and provides a statistical test to detect possibly complex treatment‐covariate interactions. Simulation studies show that this test has adequate type‐I error rate recovery as well as power when reasonable window sizes are chosen. When applied to eight breast cancer trials, Meta‐STEPP suggests that chemotherapy is less effective for tumors with high estrogen receptor expression compared with those with low expression. Copyright © 2016 John Wiley & Sons, Ltd.     

Bayesian quantile regression‐based nonlinear mixed‐effects joint models for time‐to‐event and longitudinal data with multiple features

This article explores Bayesian joint models for a quantile of longitudinal response, mismeasured covariate and event time outcome with an attempt to (i) characterize the entire conditional distribution of the response variable based on quantile regression that may be more robust to outliers and misspecification of error distribution; (ii) tailor accuracy from measurement error, evaluate non‐ignorable missing observations, and adjust departures from normality in covariate; and (iii) overcome shortages of confidence in specifying a time‐to‐event model. When statistical inference is carried out for a longitudinal data set with non‐central location, non‐linearity, non‐normality, measurement error, and missing values as well as event time with being interval censored, it is important to account for the simultaneous treatment of these data features in order to obtain more reliable and robust inferential results. Toward this end, we develop Bayesian joint modeling approach to simultaneously estimating all parameters in the three models: quantile regression‐based nonlinear mixed‐effects model for response using asymmetric Laplace distribution, linear mixed‐effects model with skew‐t distribution for mismeasured covariate in the presence of informative missingness and accelerated failure time model with unspecified nonparametric distribution for event time. We apply the proposed modeling approach to analyzing an AIDS clinical data set and conduct simulation studies to assess the performance of the proposed joint models and method. Copyright © 2016 John Wiley & Sons, Ltd.     

On the estimation of intracluster correlation for time‐to‐event outcomes in cluster randomized trials

Cluster randomized trials (CRTs) involve the random assignment of intact social units rather than independent subjects to intervention groups. Time‐to‐event outcomes often are endpoints in CRTs. Analyses of such data need to account for the correlation among cluster members. The intracluster correlation coefficient (ICC) is used to assess the similarity among binary and continuous outcomes that belong to the same cluster. However, estimating the ICC in CRTs with time‐to‐event outcomes is a challenge because of the presence of censored observations. The literature suggests that the ICC may be estimated using either censoring indicators or observed event times. A simulation study explores the effect of administrative censoring on estimating the ICC. Results show that ICC estimators derived from censoring indicators or observed event times are negatively biased. Analytic work further supports these results. Observed event times are preferred to estimate the ICC under minimum frequency of administrative censoring. To our knowledge, the existing literature provides no practical guidance on the estimation of ICC when substantial amount of administrative censoring is present. The results from this study corroborate the need for further methodological research on estimating the ICC for correlated time‐to‐event outcomes. Copyright © 2016 John Wiley & Sons, Ltd.     

Two‐stage dose finding for cytostatic agents in phase I oncology trials

Conventional dose‐finding methods in oncology are mainly developed for cytotoxic agents with the aim of finding the maximum tolerated dose. In phase I clinical trials with cytostatic agents, such as targeted therapies, designs with toxicity endpoints alone may not work well. For cytostatic agents, the goal is often to find the most efficacious dose that is still tolerable, although these agents are typically less toxic than cytotoxic agents and their efficacy may not monotonically increase with the dose. To effectively differentiate doses for cytostatic agents, we develop a two‐stage dose‐finding procedure by first identifying the toxicity upper bound of the searching range through dose escalation and then determining the most efficacious dose through dose de‐escalation while toxicity is continuously monitored. In oncology, treatment efficacy often takes a relatively long period to exhibit compared with toxicity. To accommodate such delayed response, we model the time to the efficacy event by redistributing the mass of the censored observation to the right and compute the fractional contribution of the censored data. We evaluate the operating characteristics of the new dose‐finding design for cytostatic agents and demonstrate its satisfactory performance through simulation studies. Copyright © 2012 John Wiley & Sons, Ltd.     

Generating survival times to simulate Cox proportional hazards models with time‐varying covariates

Simulations and Monte Carlo methods serve an important role in modern statistical research. They allow for an examination of the performance of statistical procedures in settings in which analytic and mathematical derivations may not be feasible. A key element in any statistical simulation is the existence of an appropriate data‐generating process: one must be able to simulate data from a specified statistical model. We describe data‐generating processes for the Cox proportional hazards model with time‐varying covariates when event times follow an exponential, Weibull, or Gompertz distribution. We consider three types of time‐varying covariates: first, a dichotomous time‐varying covariate that can change at most once from untreated to treated (e.g., organ transplant); second, a continuous time‐varying covariate such as cumulative exposure at a constant dose to radiation or to a pharmaceutical agent used for a chronic condition; third, a dichotomous time‐varying covariate with a subject being able to move repeatedly between treatment states (e.g., current compliance or use of a medication). In each setting, we derive closed‐form expressions that allow one to simulate survival times so that survival times are related to a vector of fixed or time‐invariant covariates and to a single time‐varying covariate. We illustrate the utility of our closed‐form expressions for simulating event times by using Monte Carlo simulations to estimate the statistical power to detect as statistically significant the effect of different types of binary time‐varying covariates. This is compared with the statistical power to detect as statistically significant a binary time‐invariant covariate. Copyright © 2012 John Wiley & Sons, Ltd.     

Design and semiparametric analysis of non‐inferiority trials with active and placebo control for censored time‐to‐event data

The clinical trial design including a test treatment, an active control and a placebo is called the gold standard design. In this paper, we develop a statistical method for planning and evaluating non‐inferiority trials with gold standard design for right‐censored time‐to‐event data. We consider both lost to follow‐up and administrative censoring. We present a semiparametric approach that only assumes the proportionality of the hazard functions. In particular, we develop an algorithm for calculating the minimal total sample size and its optimal allocation to treatment groups such that a desired power can be attained for a specific parameter constellation under the alternative. For the purpose of sample size calculation, we assume the endpoints to be Weibull distributed. By means of simulations, we investigate the actual type I error rate, power and the accuracy of the calculated sample sizes. Finally, we compare our procedure with a previously proposed procedure assuming exponentially distributed event times. To illustrate our method, we consider a double‐blinded, randomized, active and placebo controlled trial in major depression. Copyright © 2013 John Wiley & Sons, Ltd.     

One‐stage individual participant data meta‐analysis models: estimation of treatment‐covariate interactions must avoid ecological bias by separating out within‐trial and across‐trial information

Stratified medicine utilizes individual‐level covariates that are associated with a differential treatment effect, also known as treatment‐covariate interactions. When multiple trials are available, meta‐analysis is used to help detect true treatment‐covariate interactions by combining their data. Meta‐regression of trial‐level information is prone to low power and ecological bias, and therefore, individual participant data (IPD) meta‐analyses are preferable to examine interactions utilizing individual‐level information. However, one‐stage IPD models are often wrongly specified, such that interactions are based on amalgamating within‐ and across‐trial information. We compare, through simulations and an applied example, fixed‐effect and random‐effects models for a one‐stage IPD meta‐analysis of time‐to‐event data where the goal is to estimate a treatment‐covariate interaction. We show that it is crucial to centre patient‐level covariates by their mean value in each trial, in order to separate out within‐trial and across‐trial information. Otherwise, bias and coverage of interaction estimates may be adversely affected, leading to potentially erroneous conclusions driven by ecological bias. We revisit an IPD meta‐analysis of five epilepsy trials and examine age as a treatment effect modifier. The interaction is ?0.011 (95% CI: ?0.019 to ?0.003; p = 0.004), and thus highly significant, when amalgamating within‐trial and across‐trial information. However, when separating within‐trial from across‐trial information, the interaction is ?0.007 (95% CI: ?0.019 to 0.005; p = 0.22), and thus its magnitude and statistical significance are greatly reduced. We recommend that meta‐analysts should only use within‐trial information to examine individual predictors of treatment effect and that one‐stage IPD models should separate within‐trial from across‐trial information to avoid ecological bias. © 2016 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.     

Survival trees for interval‐censored survival data

Interval‐censored data, in which the event time is only known to lie in some time interval, arise commonly in practice, for example, in a medical study in which patients visit clinics or hospitals at prescheduled times and the events of interest occur between visits. Such data are appropriately analyzed using methods that account for this uncertainty in event time measurement. In this paper, we propose a survival tree method for interval‐censored data based on the conditional inference framework. Using Monte Carlo simulations, we find that the tree is effective in uncovering underlying tree structure, performs similarly to an interval‐censored Cox proportional hazards model fit when the true relationship is linear, and performs at least as well as (and in the presence of right‐censoring outperforms) the Cox model when the true relationship is not linear. Further, the interval‐censored tree outperforms survival trees based on imputing the event time as an endpoint or the midpoint of the censoring interval. We illustrate the application of the method on tooth emergence data.     

Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time‐to‐event endpoints

Conventional phase II trials using binary endpoints as early indicators of a time‐to‐event outcome are not always feasible. Uveal melanoma has no reliable intermediate marker of efficacy. In pancreatic cancer and viral clearance, the time to the event of interest is short, making an early indicator unnecessary. In the latter application, Weibull models have been used to analyse corresponding time‐to‐event data. Bayesian sample size calculations are presented for single‐arm and randomised phase II trials assuming proportional hazards models for time‐to‐event endpoints. Special consideration is given to the case where survival times follow the Weibull distribution. The proposed methods are demonstrated through an illustrative trial based on uveal melanoma patient data. A procedure for prior specification based on knowledge or predictions of survival patterns is described. This enables investigation into the choice of allocation ratio in the randomised setting to assess whether a control arm is indeed required. The Bayesian framework enables sample sizes consistent with those used in practice to be obtained. When a confirmatory phase III trial will follow if suitable evidence of efficacy is identified, Bayesian approaches are less controversial than for definitive trials. In the randomised setting, a compromise for obtaining feasible sample sizes is a loss in certainty in the specified hypotheses: the Bayesian counterpart of power. However, this approach may still be preferable to running a single‐arm trial where no data is collected on the control treatment. This dilemma is present in most phase II trials, where resources are not sufficient to conduct a definitive trial. Copyright © 2015 John Wiley & Sons, Ltd.     

Time‐to‐event data with time‐varying biomarkers measured only at study entry,with applications to Alzheimer's disease

Relating time‐varying biomarkers of Alzheimer's disease to time‐to‐event using a Cox model is complicated by the fact that Alzheimer's disease biomarkers are sparsely collected, typically only at study entry; this is problematic since Cox regression with time‐varying covariates requires observation of the covariate process at all failure times. The analysis might be simplified by using study entry as the time origin and treating the time‐varying covariate measured at study entry as a fixed baseline covariate. In this paper, we first derive conditions under which using an incorrect time origin of study entry results in consistent estimation of regression parameters when the time‐varying covariate is continuous and fully observed. We then derive conditions under which treating the time‐varying covariate as fixed at study entry results in consistent estimation. We provide methods for estimating the regression parameter when a functional form can be assumed for the time‐varying biomarker, which is measured only at study entry. We demonstrate our analytical results in a simulation study and apply our methods to data from the Rush Religious Orders Study and Memory and Aging Project and data from the Alzheimer's Disease Neuroimaging Initiative.     

A Bayesian mixture of semiparametric mixed‐effects joint models for skewed‐longitudinal and time‐to‐event data

In longitudinal studies, it is of interest to investigate how repeatedly measured markers in time are associated with a time to an event of interest, and in the mean time, the repeated measurements are often observed with the features of a heterogeneous population, non‐normality, and covariate measured with error because of longitudinal nature. Statistical analysis may complicate dramatically when one analyzes longitudinal–survival data with these features together. Recently, a mixture of skewed distributions has received increasing attention in the treatment of heterogeneous data involving asymmetric behaviors across subclasses, but there are relatively few studies accommodating heterogeneity, non‐normality, and measurement error in covariate simultaneously arose in longitudinal–survival data setting. Under the umbrella of Bayesian inference, this article explores a finite mixture of semiparametric mixed‐effects joint models with skewed distributions for longitudinal measures with an attempt to mediate homogeneous characteristics, adjust departures from normality, and tailor accuracy from measurement error in covariate as well as overcome shortages of confidence in specifying a time‐to‐event model. The Bayesian mixture of joint modeling offers an appropriate avenue to estimate not only all parameters of mixture joint models but also probabilities of class membership. Simulation studies are conducted to assess the performance of the proposed method, and a real example is analyzed to demonstrate the methodology. The results are reported by comparing potential models with various scenarios. Copyright © 2015 John Wiley & Sons, Ltd.     

Inference on treatment‐covariate interaction based on a nonparametric measure of treatment effects and censored survival data

The investigation of the treatment‐covariate interaction is of considerable interest in the design and analysis of clinical trials. With potentially censored data observed, non‐parametric and semi‐parametric estimates and associated confidence intervals are proposed in this paper to quantify the interactions between the treatment and a binary covariate. In addition, comparison of interactions between the treatment and two covariates are also considered. The proposed approaches are evaluated and compared by Monte Carlo simulations and applied to a real data set from a cancer clinical trial. Copyright © 2016 John Wiley & Sons, Ltd.     

Meta‐analysis of aggregate data on medical events

Meta‐analyses of clinical trials often treat the number of patients experiencing a medical event as binomially distributed when individual patient data for fitting standard time‐to‐event models are unavailable. Assuming identical drop‐out time distributions across arms, random censorship, and low proportions of patients with an event, a binomial approach results in a valid test of the null hypothesis of no treatment effect with minimal loss in efficiency compared with time‐to‐event methods. To deal with differences in follow‐up—at the cost of assuming specific distributions for event and drop‐out times—we propose a hierarchical multivariate meta‐analysis model using the aggregate data likelihood based on the number of cases, fatal cases, and discontinuations in each group, as well as the planned trial duration and groups sizes. Such a model also enables exchangeability assumptions about parameters of survival distributions, for which they are more appropriate than for the expected proportion of patients with an event across trials of substantially different length. Borrowing information from other trials within a meta‐analysis or from historical data is particularly useful for rare events data. Prior information or exchangeability assumptions also avoid the parameter identifiability problems that arise when using more flexible event and drop‐out time distributions than the exponential one. We discuss the derivation of robust historical priors and illustrate the discussed methods using an example. We also compare the proposed approach against other aggregate data meta‐analysis methods in a simulation study. Copyright © 2016 John Wiley & Sons, Ltd.     

Sizing clinical trials when comparing bivariate time‐to‐event outcomes

Clinical trials with multiple primary time‐to‐event outcomes are common. Use of multiple endpoints creates challenges in the evaluation of power and the calculation of sample size during trial design particularly for time‐to‐event outcomes. We present methods for calculating the power and sample size for randomized superiority clinical trials with two correlated time‐to‐event outcomes. We do this for independent and dependent censoring for three censoring scenarios: (i) the two events are non‐fatal; (ii) one event is fatal (semi‐competing risk); and (iii) both are fatal (competing risk). We derive the bivariate log‐rank test in all three censoring scenarios and investigate the behavior of power and the required sample sizes. Separate evaluations are conducted for two inferential goals, evaluation of whether the test intervention is superior to the control on: (1) all of the endpoints (multiple co‐primary) or (2) at least one endpoint (multiple primary). Copyright © 2017 John Wiley & Sons, Ltd.     

A pattern‐mixture model approach for handling missing continuous outcome data in longitudinal cluster randomized trials

We extend the pattern‐mixture approach to handle missing continuous outcome data in longitudinal cluster randomized trials, which randomize groups of individuals to treatment arms, rather than the individuals themselves. Individuals who drop out at the same time point are grouped into the same dropout pattern. We approach extrapolation of the pattern‐mixture model by applying multilevel multiple imputation, which imputes missing values while appropriately accounting for the hierarchical data structure found in cluster randomized trials. To assess parameters of interest under various missing data assumptions, imputed values are multiplied by a sensitivity parameter, k, which increases or decreases imputed values. Using simulated data, we show that estimates of parameters of interest can vary widely under differing missing data assumptions. We conduct a sensitivity analysis using real data from a cluster randomized trial by increasing k until the treatment effect inference changes. By performing a sensitivity analysis for missing data, researchers can assess whether certain missing data assumptions are reasonable for their cluster randomized trial.     

Assessing temporal agreement between central and local progression‐free survival times

In oncology clinical trials, progression‐free survival (PFS), generally defined as the time from randomization until disease progression or death, has been a key endpoint to support licensing approval. In the U.S. Food and Drug Administration guidance for industry, May 2007, concerning the PFS as the primary or co‐primary clinical trial endpoint, it is recommended to have tumor assessments verified by an independent review committee blinded to study treatments, especially in open‐label studies. It is considered reassuring about the lack of reader‐evaluation bias if treatment effect estimates from the investigators' and independent review committees' evaluations agree. The agreement between these evaluations may vary for subjects with short or long PFS, while there exist no such statistical quantities that can completely account for this temporal pattern of agreements. Therefore, in this paper, we propose a new method to assess temporal agreement between two time‐to‐event endpoints, while the two event times are assumed to have a positive probability of being identical. This method measures agreement in terms of the two event times being identical at a given time or both being greater than a given time. Overall scores of agreement over a period of time are also proposed. We propose a maximum likelihood estimation to infer the proposed agreement measures using empirical data, accounting for different censoring mechanisms, including reader's censoring (event from one reader dependently censored by event from the other reader). The proposed method is demonstrated to perform well in small samples via extensive simulation studies and is illustrated through a head and neck cancer trial. Copyright © 2014 John Wiley & Sons, Ltd.     

Assessing the impact of selection bias on test decisions in trials with a time‐to‐event outcome

If past treatment assignments are unmasked, selection bias may arise even in randomized controlled trials. The impact of such bias can be measured by considering the type I error probability. In case of a normally distributed outcome, there already exists a model accounting for selection bias that permits calculating the corresponding type I error probabilities. To model selection bias for trials with a time‐to‐event outcome, we introduce a new biasing policy for exponentially distributed data. Using this biasing policy, we derive an exact formula to compute type I error probabilities whenever an F‐test is performed and no observations are censored. Two exemplary settings, with and without random censoring, are considered in order to illustrate how our results can be applied to compare distinct randomization procedures with respect to their performance in the presence of selection bias. © 2017 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.     

A multivariate cure model for left‐censored and right‐censored data with application to colorectal cancer screening patterns

We develop a multivariate cure survival model to estimate lifetime patterns of colorectal cancer screening. Screening data cover long periods of time, with sparse observations for each person. Some events may occur before the study begins or after the study ends, so the data are both left‐censored and right‐censored, and some individuals are never screened (the ‘cured’ population). We propose a multivariate parametric cure model that can be used with left‐censored and right‐censored data. Our model allows for the estimation of the time to screening as well as the average number of times individuals will be screened. We calculate likelihood functions based on the observations for each subject using a distribution that accounts for within‐subject correlation and estimate parameters using Markov chain Monte Carlo methods. We apply our methods to the estimation of lifetime colorectal cancer screening behavior in the SEER‐Medicare data set. Copyright © 2016 John Wiley & Sons, Ltd.     

Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint

We consider estimation of treatment effects in two‐stage adaptive multi‐arm trials with a common control. The best treatment is selected at interim, and the primary endpoint is modeled via a Cox proportional hazards model. The maximum partial‐likelihood estimator of the log hazard ratio of the selected treatment will overestimate the true treatment effect in this case. Several methods for reducing the selection bias have been proposed for normal endpoints, including an iterative method based on the estimated conditional selection biases and a shrinkage approach based on empirical Bayes theory. We adapt these methods to time‐to‐event data and compare the bias and mean squared error of all methods in an extensive simulation study and apply the proposed methods to reconstructed data from the FOCUS trial. We find that all methods tend to overcorrect the bias, and only the shrinkage methods can reduce the mean squared error. © 2017 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.